NCT07209488 · Rutgers, The State University of New Jersey
Acquired Dyslexia Modeling and Treatment
(AMT)
What this study is about
This study is a low-risk, early phase 1, conducted at multiple hospitals trial to test the use of a computational (neural network) cognitive model of reading to simulate acquired dyslexia and its treatment. The aim is to determine whether there is an advantage to receiving the treatment the model predicts to be advantageous compared to the alternative treatment.
View original scientific description
This study is a low-risk, early phase 1, multicenter trial to test the use of a computational (neural network) cognitive model of reading to simulate acquired dyslexia and its treatment. The aim is to determine whether there is an advantage to receiving the treatment the model predicts to be advantageous compared to the alternative treatment. All participants will receive two full rounds of treatment. A round of treatment will consist of either phonomotor treatment (PMT) or semantic feature analysis (SFA) for 60 hours, distributed over 5 days a week for 2 hours a day.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Fluent in English as a first language pre-stroke by self report.
- Normal or corrected-to-normal vision.
- Normal or aided hearing.
- Left hemisphere ischemic or hemorrhagic stroke (as verified by a structural brain scan).
- Impaired reading as confirmed by significant impairment in the Basic Skills cluster of the Woodcock Reading Mastery Test - III.
Exclusion criteria
- Diagnosed pre-stroke neurological disease affecting the brain other than left hemisphere stroke.
- Severe apraxia of speech (determined by consensus judgment among speech-language pathologists).
- History of learning disabilities such as developmental dyslexia or current self-reported major psychiatric disorders.
- Inability to undergo, or provide a copy of, a post-stroke brain imaging scan.
Where
- Tallahassee, Florida
- Baltimore, Maryland
- West Orange, New Jersey
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 6, 2026 · Source of record for eligibility and locations